Introducing Melanoma Institute Australia's Conjoint Medical Directors
14 March 2017
Two of the world’s best minds in melanoma have taken over the academic and clinical leadership of Melanoma Institute Australia (MIA). Professor Georgina Long and Professor Richard Scolyer are the new Conjoint Medical Directors of MIA, and are shaping the future direction of melanoma research, treatment and education.
Professor Long is a world-renowned clinical medical oncologist and melanoma researcher who is also President Elect for the prestigious international Society for Melanoma Research. She leads an extensive clinical trials team and research laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma.
Professor Scolyer is a world- leading surgical pathologist and melanoma researcher who has authored more than 450 seminal publications on this disease. Professor Scolyer’s expertise has already delivered exponential improvements in diagnosis and the staging of melanoma which determines a patient’s treatment pathway.
Together with their colleagues at MIA, they are changing the face of melanoma diagnosis and treatment in Australia and around the world.
‘Quite simply, I want to make a difference,” Professor Long said. ‘’I’d love to eradicate melanoma and put ourselves out of a job. That is the ultimate goal.”
‘Even if we haven’t eradicated melanoma in the next five years, I’d like to think we can control it long term so people don’t die of this disease,” Professor Scolyer added.
Sharing the Medical Director role means double the expertise and double the perspective on challenges. Both Professors believe their partnership will be crucial to leading Melanoma Institute Australia towards breaking new ground in melanoma diagnosis and treatment.
‘We know that ultimately prevention is better than cure, so we have to attack the disease at different levels from education, prevention, screening, early diagnosis, and by providing the best early treatment for the best outcomes,’ Professor Scolyer said.
‘The key to tackling melanoma is definitely collaboration, communication and sharing knowledge,” Professor Long added.
Melanoma Institute Australia is the leading centre in the world with a single focus on melanoma care, research and education.
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread
Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.
COVID restrictions continue to impact fundraising for melanoma services in Riverina.
Ben Garrow lost his life to melanoma. In his honour his family has established a scholarship to support a PhD student whose work focuses on saving lives from melanoma.
More than 150 clinicians, researchers and MIA staff gathered online to share research highlights.
Independent researchers at The University of Sydney are seeking patient feedback.
A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.
Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients.
MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!
Postponed to early 2022. Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!
Riverina patients gain access to potentially life saving immunotherapy treatment close to home.
MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia.
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.
The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.